We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Crinetics Pharmaceuticals Inc
3 own
3 watching
Current Price
$22.1
$0.13
(0.59%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,190.68M
52-Week High
24.58
52-Week Low
15.23
Average Volume
0.33M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,190.68M52-Week High24.5852-Week Low15.23Average Volume0.33MDividend Yield--P/E Ratio--What does the Crinetics Pharmaceuticals Inc do?
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing s and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Read More
How much money does Crinetics Pharmaceuticals Inc make?
News & Events about Crinetics Pharmaceuticals Inc.
Globe Newswire
3 months ago
SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that company management will participate in a fireside chat at the annual SVB Securities Global Biopharma Conference, which is being held in a virtual format February 14-16, 2023. Details of the ...
Globe Newswire
4 months ago
Efforts to further increase commercial readiness ongoing as Phase 3 PATHFNDR trials of paltusotine in acromegaly approach topline data readouts which are expected in 2H 2023 Phase 2 trial of paltusotine in carcinoid syndrome on track for topline data in 2H 2023 Clinical trials of CRN04894 in ACTH-...
Globe Newswire
6 months ago
SAN DIEGO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today provided an update on its development program for CRN04777, an investigational, oral somatostatin receptor type 5 (SST5) agonist being developed as a treatment for congenital hyperinsulinism (HI). On ...
Globe Newswire
6 months ago
SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc.(Nasdaq: CRNX), today announced that company management will participate in a fireside chat and 1x1 investor meetings at the 5th Annual Evercore ISI HealthCONx Conference being held virtually November 29 December 1, 2022. ...
Globe Newswire
9 months ago
SAN DIEGO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that Monica R. Gadelha, MD, PhD, professor of endocrinology at the Medical School of the Universidade Federal do Rio de Janeiro and a principal investigator in the Phase 2 ACROBAT program, will be ...
Frequently Asked Questions
Frequently Asked Questions
What is Crinetics Pharmaceuticals Inc share price today?
Can Indians buy Crinetics Pharmaceuticals Inc shares?
How can I buy Crinetics Pharmaceuticals Inc shares from India?
Can Fractional shares of Crinetics Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Crinetics Pharmaceuticals Inc stocks?
What is today’s traded volume of Crinetics Pharmaceuticals Inc?
What is today’s market capitalisation of Crinetics Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Crinetics Pharmaceuticals Inc?
What percentage is Crinetics Pharmaceuticals Inc down from its 52-Week High?
What percentage is Crinetics Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$22.1
$0.13
(0.59%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.